---
title: "Panlong Pharmaceutical: Cancel the special account for raised funds used for traditional Chinese medicine projects"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274943177.md"
description: "Panlong Pharmaceutical announced that in September 2023, the company issued 9.3527 million shares to specific targets at an issuance price of 32.29 yuan per share, raising a total of 302 million yuan, with a net amount of 295 million yuan. The company previously signed a \"Three-party Supervision Agreement on Raised Funds\" with the sponsoring institution and related banks. As of the announcement disclosure date, the account at the Bank of China Xi'an Software Park Branch for the \"Traditional Chinese Medicine Formula Granule R&D and Industrialization Project\" has no balance and will be canceled in 2026, with the corresponding supervision agreement terminating simultaneously"
datetime: "2026-02-05T09:00:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274943177.md)
  - [en](https://longbridge.com/en/news/274943177.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274943177.md)
---

# Panlong Pharmaceutical: Cancel the special account for raised funds used for traditional Chinese medicine projects

Panlong Pharmaceutical announced that in September 2023, the company issued 9.3527 million shares to specific targets at an issue price of 32.29 yuan per share, raising a total of 302 million yuan, with a net amount of 295 million yuan. The company previously signed a "Three-party Supervision Agreement on Raised Funds" with the sponsoring institution and related banks. As of the announcement date, the account at the Xi'an Software Park branch of Bank of China for the "Traditional Chinese Medicine Formula Granule R&D and Industrialization Project" has no balance and will be canceled in 2026, with the corresponding supervision agreement terminating simultaneously

### Related Stocks

- [002864.CN](https://longbridge.com/en/quote/002864.CN.md)

## Related News & Research

- [Menroc Asset Management Sees Growing Preference for Income-Focused Investments](https://longbridge.com/en/news/290526283.md)
- [Coiled Therapeutics: AO-252 delivers promising clinical results and commercial potential as the only clinical-stage TACC3 inhibitor](https://longbridge.com/en/news/290784764.md)
- [09:47 ETADAMA Announces Launch of Novali™, a High-Load Liquid Pyroxasulfone Herbicide for Row Crops](https://longbridge.com/en/news/290704210.md)
- [Edward Jones takes minority stake in Aquiline-backed Quicken](https://longbridge.com/en/news/290695157.md)
- [19:16 ETCAI Software Acquires PlanetTogether; Strengthening Advanced Planning and Scheduling Capabilities Across Manufacturing](https://longbridge.com/en/news/290749215.md)